Big Beat for Gilead on Rising Sovaldi Revenue

Big Beat for Gilead on Rising Sovaldi Revenue Play

July 23 (Bloomberg) -- Gilead Sciences, maker of the hepatitis C pill Sovaldi, doubled its sales forecast for the year on better-than-estimated revenue from the blockbuster pill. Bloomberg’s Olivia Sterns reports on “Street Smart.” (Source: Bloomberg)

  • On Air Now

    Bloomberg Pursuits Watch Now

  • Next

    Charlie Rose

blog comments powered by Disqus